Table 2.
Clinical outcomes in the final analysis population
| HR (95% CI) | p value | |
|---|---|---|
| Primary endpoint | ||
| Unadjusted | 0·95 (0·76–1·20) | 0·69 |
| Adjusted for sex | 1·01 (0·81–1·28) | 0·90 |
| Adjusted for obesity | 0·99 (0·78–1·26) | 0·92 |
| Adjusted for diabetes | 0·96 (0·76–1·20) | 0·69 |
| Adjusted for cardiovascular disease | 0·94 (0·75–1·18) | 0·59 |
| Adjusted for all the above | 1·07 (0·62–1·84) | 0·82 |
| Mortality (secondary endpoint) | ||
| Unadjusted | 0·51 (0·27–0·95) | 0·034 |
| Adjusted for sex | 0·47 (0·25–0·89) | 0·019 |
| Adjusted for obesity | 0·46 (0·23–0·92) | 0·029 |
| Adjusted for diabetes | 0·54 (0·29–1·02) | 0·057 |
| Adjusted for cardiovascular disease | 0·54 (0·29–1·01) | 0·055 |
| Adjusted for all the above | 0·52 (0·26–1·05) | 0·068 |
| Need for mechanical ventilation (secondary endpoint) | ||
| Unadjusted | 1·07 (0·63–1·80) | 0·81 |
| Adjusted for sex | 0·98 (0·58–1·67) | 0·95 |
| Adjusted for obesity | 1·08 (0·63–1·86) | 0·77 |
| Adjusted for diabetes | 1·13 (0·66–1·91) | 0·66 |
| Adjusted for cardiovascular disease | 1·06 (0·62–1·79) | 0·84 |
| Adjusted for all the above | 1·02 (0·80–1·30) | 0·87 |
All HRs are for the imatinib group versus the placebo group. The final analysis population consisted of 188 patients in the placebo group and 197 patients in the imatinib group. HRs and 95% CIs were calculated by use of Cox regression analysis and adjusted for sex and the indicated comorbidities. HR=hazard ratio.